Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-03-12

Clinical Trial Update: Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibrutinib after intensive induction in previously untreated mantle cell lymphoma patients; status unavailable with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ibrutinib (ibrutinib)

Snippet

Sponsor: Northwestern University | Conditions: Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Status: UNKNOWN | Results posted: 2024-03-12